We use cookies on this site to enable your digital experience. By continuing to use this site, you are agreeing to our cookie policy. close

The FTC's Ongoing Opposition To Reverse Payments

Law360 (May 8, 2008, 12:00 AM EDT) -- The “Drug Price Competition and Patent Term Restoration Act of 1984,” more often called “Hatch-Waxman,” regulates the generic drug industry in the United States. Hatch-Waxman reflects an attempt by Congress to balance incentives for innovation in the pharmaceutical industry with greater public access to the drugs produced by that industry.

These incentives include restoring a period of patent protection to the innovator drug companies lost while waiting for regulatory approval of a drug. At the same time, Hatch-Waxman is intended to provide lower medical costs by...
To view the full article, register now.
Law360 Pro Say Podcast
Check out Law360's new podcast, Pro Say, which offers a weekly recap of both the biggest stories and hidden gems from the world of law.